financetom
Business
financetom
/
Business
/
JD.com's Q2 Adjusted Earnings, Revenue Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JD.com's Q2 Adjusted Earnings, Revenue Increase
Aug 15, 2024 3:59 AM

06:31 AM EDT, 08/15/2024 (MT Newswires) -- JD.com ( JD ) reported Q2 adjusted earnings Thursday of 9.36 renminbi ($1.29) per American depositary share, up from 5.39 renminbi per ADS a year earlier.

Analysts polled by Capital IQ expected 6.19 renminbi.

Revenue for the quarter ended June 30 was 291.40 billion renminbi, up from 287.93 billion renminbi a year earlier.

Analysts surveyed by Capital IQ expected 291.67 billion renminbi.

Shares of JD.com ( JD ) rose more than 3% in recent premarket activity Thursday.

Price: 26.80, Change: +0.90, Percent Change: +3.47

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Lead Real Estate to Pay Special Cash Dividend Sept. 30 to Shareholders of Record June 30
--Lead Real Estate to Pay Special Cash Dividend Sept. 30 to Shareholders of Record June 30
Jun 24, 2024
11:17 AM EDT, 06/24/2024 (MT Newswires) -- Price: 7.23, Change: -1.47, Percent Change: -16.90 ...
Market Chatter: BlackSuit Blamed for CDK Global Cyberattack
Market Chatter: BlackSuit Blamed for CDK Global Cyberattack
Jun 24, 2024
11:17 AM EDT, 06/24/2024 (MT Newswires) -- A hacking group called BlackSuit is responsible for the ransomware attack on CDK Global (CDK) that has brought car sales nationwide to a standstill, Bloomberg reported, citing Allan Liska, a threat analyst at security firm Recorded Future. CDK did not immediately respond to a request for comment from MT Newswires. (Market Chatter news...
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise
Jun 24, 2024
11:19 AM EDT, 06/24/2024 (MT Newswires) -- InflaRx ( IFRX ) said Monday that the Biomedical Advanced Research and Development Authority has selected its anti-inflammatory drug Gohibic, or vilobelimab, for a Phase 2 clinical trial evaluating options to treat acute respiratory distress syndrome. The trial, expected to start later this year, will assess 600 hospitalized adults and the primary endpoint...
Chevron forecasts second-quarter production impact
Chevron forecasts second-quarter production impact
Jun 24, 2024
June 24 (Reuters) - Energy major Chevron ( CVX ) said on Monday it expects upstream turnarounds and downtime to impact 65,000 barrels of oil equivalent per day in production in the second quarter mostly driven by Tengizchevroil in Kazakhstan and several Gulf of Mexico assets. (Reporting by Sourasis Bose in Bengaluru) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved